Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 10/20 | 0.52 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL7252923 | 0.95 | HTR7 (0.49) | HTR7HTR2AHTR2CPRMT5HTR6 | |
| SCHEMBL18239699 | 0.85 | HTR7 (0.57) | HTR7HTR2AHTR2CPRMT5HTR6 | |
| Fumaric Acid SCHEMBL7677263 | 0.85 | FGFR1 (0.42) | HTR7HTR2AHTR2CPRMT5 | |
| SCHEMBL3478164 | 0.85 | HTR2A (0.63) | HTR7HTR2AHTR2C | |
| Quinoline SCHEMBL27994088 | 0.82 | CYP1A2 (0.51) | HTR7HTR2AHTR2CPRMT5 | |
| SCHEMBL24144443 | 0.80 | HTR7 (0.63) | HTR7HTR2AHTR2CPRMT5HTR6 | |
| SCHEMBL24142902 | 0.80 | HTR7 (0.63) | HTR7HTR2AHTR2CPRMT5PRMT1 | |
| SCHEMBL3785959 | 0.80 | FGFR1 (0.48) | HTR7HTR2AHTR2CHTR6 | |
| SCHEMBL7256513 | 0.79 | HTR7 (0.51) | HTR7HTR2AHTR2CHTR6 | |
| SCHEMBL10193356 | 0.78 | HTR2C (0.62) | HTR7HTR2AHTR2CPRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025082069-A1 | COMPOUND BINDING TO CRBN PROTEIN AND DEGRADATION AGENT OF PROTEIN | 中国海洋大学 | 2025-04-24 | — | — | WO | disclosed |
| EP-3615514-B1 | PROPIONIC ACID DERIVATIVES AND METHODS OF USE THEREOF | AVIARA PHARMACEUTICALS INC (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-110914242-B | Propionic acid derivatives and methods of use thereof | 阿维亚拉药品有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-3298003-B1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2023-04-19 | — | — | EP | disclosed |
| CN-110452235-B | Fluorine-containing isoxazole compound and preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2023-02-17 | — | — | CN | disclosed |
| CN-107531717-B | Aza-pyridone compounds and uses thereof | 詹森生物制药有限公司 | 2021-07-27 | — | — | CN | disclosed |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | AVIARA PHARMACEUTICALS, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-20200095227-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-26 | — | — | US | disclosed |
| CN-1124262-C | Indole derivatives as endothelin receptor antagonists | PFIZER (US) | 2003-10-15 | — | — | CN | disclosed |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-07-03 | — | — | US | disclosed |
| US-6384070-B2 | RESTENOSIS, KIDNEY DISEASES, LUNG DISEASES | PFIZER INC. | 2002-05-07 | — | — | US | disclosed |
| US-6306852-B1 | INDOLE DERIVATIVES USEFUL IN THE TREATMENT OF A VARIETY OF DISEASES INCLUDING RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION, AND TO PHARMACEUTICAL FORMULATIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | RAWSON DAVID JAMES (GB) | 2001-08-16 | — | — | US | disclosed |
| US-6136843-A | CARDIOVASCULAR DISORDERS; KIDNEY DISORDERS | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| US-6017945-A | USEFUL IN THE TREATMENT OF RESTENOSIS, RENAL FAILURE AND PULMONARY HYPERTENSION | PFIZER INC. (US) | 2000-01-25 | — | — | US | disclosed |
| CN-1216531-A | Indole derivatives as endothelin receptor antagonists | PFIZER (US) | 1999-05-12 | — | — | CN | disclosed |
| EP-0901470-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1999-03-17 | — | — | EP | disclosed |
| WO-1997043260-A1 | INDOLE DERIVATIVES USEFUL AS ENDOTHELIN RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1997-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010014677-A1 | Restenosis, kidney diseases, lung diseases | NR1H2, NR1H3, NR1H4 | HTR7 582/4885HTR2A 1047/4885HTR2C 879/4885 |
| US-20200095227-A1 | BENZOIMIDAZOLE DERIVATIVES AS PAD4 INHIBITORS | PADI4, PADI1, PADI2 | HTR7 4395/4885HTR2A 4841/4885HTR2C 4706/4885 |
| US-10875875-B2 | Propionic acid derivatives and methods of use thereof | ITGB3, ITGA1, ITGB5 | HTR7 877/4885HTR2A 1619/4885HTR2C 2044/4885 |
| US-20030125371-A1 | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | TFPI, SERPINE1, PLAT | HTR7 414/4885HTR2A 325/4885HTR2C 564/4885 |
| US-10815218-B2 | Benzoimidazole derivatives as PAD4 inhibitors | PADI4, PADI1, PADI2 | HTR7 4395/4885HTR2A 4841/4885HTR2C 4706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.